Calidi Biotherapeutics Stock Analysis

CLDI Stock   1.59  0.17  9.66%   
Calidi Biotherapeutics is undervalued with Real Value of 3.68 and Target Price of 10.0. The main objective of Calidi Biotherapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Calidi Biotherapeutics is worth, separate from its market price. There are two main types of Calidi Biotherapeutics' stock analysis: fundamental analysis and technical analysis.
The Calidi Biotherapeutics stock is traded in the USA on NYSE MKT Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Calidi Biotherapeutics' ongoing operational relationships across important fundamental and technical indicators.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Calidi Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
For more detail on how to invest in Calidi Stock please use our How to Invest in Calidi Biotherapeutics guide.

Calidi Stock Analysis Notes

About 48.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.59. Calidi Biotherapeutics had not issued any dividends in recent years. For more info on Calidi Biotherapeutics please contact Allan Camaisa at 858 794 9600 or go to https://calidibio.com.

Calidi Biotherapeutics Investment Alerts

Calidi Biotherapeutics is way too risky over 90 days horizon
Calidi Biotherapeutics may become a speculative penny stock
Calidi Biotherapeutics appears to be risky and price may revert if volatility continues
Calidi Biotherapeutics has high likelihood to experience some financial distress in the next 2 years
Calidi Biotherapeutics was previously known as Exchange Traded Concepts and was traded on NASDAQ Exchange under the symbol FLAG.
Net Loss for the year was (29.22 M) with profit before overhead, payroll, taxes, and interest of 31 K.
Calidi Biotherapeutics generates negative cash flow from operations
Calidi Biotherapeutics has a very weak financial position based on the latest SEC disclosures
About 48.0% of the company shares are held by company insiders
Latest headline from news.google.com: CLDI - Calidi Biotherapeutics, Inc. Latest Stock News Market Updates - StockTitan

Calidi Biotherapeutics Upcoming and Recent Events

Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Calidi Biotherapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
13th of February 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View
13th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Calidi Largest EPS Surprises

Earnings surprises can significantly impact Calidi Biotherapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2023-11-14
2023-09-30-0.17-0.140.0317 
2024-03-15
2023-12-31-0.2-0.48-0.28140 
View All Earnings Estimates

Calidi Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 34.43 M.

Management Efficiency

Calidi Biotherapeutics has return on total asset (ROA) of (1.7298) % which means that it has lost $1.7298 on every $100 spent on assets. This is way below average. Calidi Biotherapeutics' management efficiency ratios could be used to measure how well Calidi Biotherapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of now, Calidi Biotherapeutics' Total Assets are increasing as compared to previous years. The Calidi Biotherapeutics' current Non Current Assets Total is estimated to increase to about 6 M, while Net Tangible Assets are projected to decrease to (47.7 M).
The analysis of Calidi Biotherapeutics' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Calidi Biotherapeutics' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Calidi Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta
0.424
Return On Assets
(1.73)

Technical Drivers

As of the 23rd of July, Calidi Biotherapeutics shows the Mean Deviation of 6.64, downside deviation of 9.92, and Risk Adjusted Performance of 0.0253. Calidi Biotherapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.

Calidi Biotherapeutics Price Movement Analysis

Execute Study
The output start index for this execution was nine with a total number of output elements of fifty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Calidi Biotherapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Calidi Biotherapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Calidi Biotherapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Calidi Biotherapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Calidi Biotherapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Calidi Biotherapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Calidi Biotherapeutics Predictive Daily Indicators

Calidi Biotherapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Calidi Biotherapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Calidi Biotherapeutics Forecast Models

Calidi Biotherapeutics' time-series forecasting models are one of many Calidi Biotherapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Calidi Biotherapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Calidi Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Calidi Biotherapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Calidi shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Calidi Biotherapeutics. By using and applying Calidi Stock analysis, traders can create a robust methodology for identifying Calidi entry and exit points for their positions.
Calidi Biotherapeutics is entity of United States. It is traded as Stock on NYSE MKT exchange.

Current Calidi Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Calidi analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Calidi analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
10.0Strong Buy2Odds
Calidi Biotherapeutics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Calidi analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Calidi stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Calidi Biotherapeutics, talking to its executives and customers, or listening to Calidi conference calls.
Calidi Analyst Advice Details

Calidi Stock Analysis Indicators

Calidi Biotherapeutics stock analysis indicators help investors evaluate how Calidi Biotherapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Calidi Biotherapeutics shares will generate the highest return on investment. By understating and applying Calidi Biotherapeutics stock analysis, traders can identify Calidi Biotherapeutics position entry and exit signals to maximize returns.
Begin Period Cash Flow590 K
Long Term Debt2.1 M
Common Stock Shares Outstanding35.5 M
Total Stockholder Equity-8.2 M
Tax Provision16 K
Property Plant And Equipment Net5.3 M
Cash1.9 M
Accounts Payable2.8 M
Net Debt918 K
50 Day M A1.6841
Total Current Liabilities10.2 M
Non Current Assets Total5.7 M
Non Currrent Assets Other143 K
Stock Based Compensation4.8 M

Complementary Tools for Calidi Stock analysis

When running Calidi Biotherapeutics' price analysis, check to measure Calidi Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Calidi Biotherapeutics is operating at the current time. Most of Calidi Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Calidi Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Calidi Biotherapeutics' price. Additionally, you may evaluate how the addition of Calidi Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Stocks Directory
Find actively traded stocks across global markets
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk